NASDAQ · Biotechnology

Kezar Life Sciences (KZR) Stock

$7.29 +0.00% NASDAQ: KZR Healthcare

Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies.

Valuation

MetricValue
Price$7.29
Market Cap$53.86M
P/E Ratio-0.96
P/B Ratio0.77
P/S Ratio0.00
EPS (TTM)$-7.66
52-Week High$7.55
52-Week Low$3.53
Dividend Yield—

Financials & Margins

MetricValue
ROE-80.00%
ROA-72.73%
ROCE-74.29%
Gross Margin—
Operating Margin—
Net Margin0.00%
Debt/Equity0.02
Current Ratio10.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$7.0M$0$0
Operating Profit$-55.0M$-71.0M$-111.0M$-91.0M$-52.0M
Net Profit$-55.0M$-68.0M$-102.0M$-84.0M$-56.0M
EPS$-1.04$-1.01$-1.40$-1.15$-7.66
Op Margin——-1591.8%——

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$218.0M$300.0M$221.0M$145.0M$77.0M
Total Liabilities$21.0M$30.0M$34.0M$28.0M$7.0M
Cash$63.0M$40.0M$35.0M$42.0M$72.0M
Borrowings$14.0M$21.0M$19.0M$16.0M$2.0M

Latest News

2 Stocks Down 44% and 30% to Buy Right Now and Hold for the Next Decade Motley Fool · Jul 17, 2026 Trump focuses on an election, but it's not the midterms. It's 2020 USA TODAY · Jul 17, 2026 Disney considers launching free streaming option for consumers TheStreet · Jul 17, 2026 Dow Jones Futures Fall, Netflix Dives, SpaceX Scrubs Launch After Latest AI Sell-Off Investor's Business Daily · Jul 17, 2026 Struggling Android phone maker prepares to pull out of US TheStreet · Jul 17, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-42.0M$-59.0M$-82.0M$-74.0M$-52.0M
Investing Cash Flow$-29.0M$-93.0M$74.0M$80.0M$92.0M
Financing Cash Flow$2.0M$1.0M$0$0$0
Net Cash Flow$42.0M$-22.0M$-5.0M$6.0M$30.0M
Free Cash Flow$-43.0M$-60.0M$-83.0M$-74.0M$-52.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-96.24%
Quick Ratio10.86
Interest Coverage—
Return 1Y—
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CCCC $3.52 -0.85% -2.54 $389.20M 0.00%
CRNX $83.81 -0.09% -8.57 $8.87B 0.00%
ERAS $17.72 -2.42% -23.45 $6.15B 0.00%
EWTX $43.52 -2.03% -14.63 $4.68B 0.00%
REPL $11.92 +0.08% -1.66 $1.00B 0.00%

About Kezar Life Sciences

Kezar Life Sciences, Inc. is a United States-based clinical-stage biopharmaceutical company focused on identifying and advancing novel small molecule therapies. Its mission is to address significant unmet medical needs in both immune-mediated diseases and various forms of cancer. The company's most advanced experimental drug is KZR-616, a specialized immunoproteasome inhibitor. This candidate is currently undergoing Phase 2 clinical evaluation for several conditions, including lupus nephritis, dermatomyositis, and polymyositis. Concurrently, KZR-616 is also in Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis. In its preclinical pipeline, Kezar is developing KZR-261, a pioneering first-in-class protein secretion inhibitor, as well as KZR-TBD, which is being investigated for its potential in oncology and immunology. The firm was founded in 2015 and is headquartered in South San Francisco, California.

Kezar Life Sciences is led by CEO Christopher J. Kirk, employs 55 people, headquartered in US, publicly traded since 2018.

Kezar Life Sciences (KZR) stock trades at $7.29 with a market capitalization of $53.86M. The stock is valued at a price-to-earnings (P/E) ratio of -0.96, price-to-book of 0.77, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.53 and $7.55, and currently trades 3.4% below its 52-week high.

On profitability, Kezar Life Sciences generates a return on equity (ROE) of -80.00%, return on capital employed of -74.29%, a net profit margin of 0.00%.

Official website: www.kezarlifesciences.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides